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and plasmacytoid DCs (PDCs) express TLR1, 6, 7, 9, and 10 
(  19, 21  –  23  ). Monocyte-derived DCs (MDDCs) express TLR1, 
2, 3, 4, 5, 6, 8, 9, and 10, but hardly any TLR7 (  24, 25  ). 
In   basophilic and eosinophilic granulocytes, substantial expres-
sion has been confi  rmed only for TLR7 in eosinophils (  26  ). 
In the lymphoid lineage, blood B cells express TLR1, 6, 7, 9, 
and 10 (  20, 23, 27  ); NK cells express TLR1, 2, 3, 5, 6, 7, and 
8 (  20  ); CD4     /     T cells express at least TLR1, 2, and 5 (  28  ); 
and eff  ector     /     CD8 T cells and     /     T cells express TLR3 
(  29, 30  ). In healthy controls, most subsets could be activated 
by the corresponding TLR agonists tested. In contrast, the range 
of blood cells in which TLR responses are aff  ected by IRAK-4 
defi  ciency remains unclear. 
  IRAK-4 defi  ciency may have an even broader impact, 
given the well-established role of IRAK-4 downstream from 
multiple IL-1Rs (  1, 31  ) and the recently proposed role of 
IRAK-4 in TCR signaling (  32  ). It is thus surprising that the fi  rst 
three patients identifi  ed were alive and well and had experi-
enced only a few infectious diseases (  1  ). To date, 21 IRAK-4  –
  defi  cient patients have been reported in individual case reports 
or small series (  1, 4  –  13, 33  –  36  ). Most presented with periph-
eral (e.g., pharyngotonsillitis, sinusitis, cellulitis, and endo-
phthalmitis) and/or invasive bacterial diseases (e.g., meningitis, 
arthritis, septicemia, and visceral abscess) caused mostly by 
  Streptococcus pneumoniae   and  Staphylococcus aureus   ( 1, 4 –  13, 33 –  36  ). 
Only seven patients also presented infectious disease caused 
by Gram-negative bacteria (  Pseudomonas aeruginosa   in most 
cases) (  1, 4  –  6, 8, 13, 33, 36  ). Although IRAK-4 defi  ciency 
appears to be more severe than initially thought (  1  ), with seven 
reported deaths (  5, 7  –  9, 13, 34, 36  ), the condition seems to 
improve with age, even without prophylaxis (  4, 6, 36  ). The 
apparent broad resistance of IRAK-4  –  defi  cient patients chal-
lenges the prevailing view that TLRs are the principal sentinels 
of innate immunity (  37  –  39  ). However, it has been diffi   cult to 
draw fi  rm conclusions in the absence of a large series of patients. 
Moreover, the rarity of infections may refl  ect the TLR-
dependent, yet IRAK-4 –  independent, induction of certain cyto-
kines in specifi  c leukocyte subsets. We thus investigated the 
contribution of human TLRs to host defense by documenting 
  Inherited IL-1R  –  associated kinase 4 (IRAK-4) defi  ciency is 
an autosomal recessive disorder that was fi  rst described in three 
unrelated children (  1  ). IRAK-4  –  defi  cient patients  ’   fi  broblasts 
and/or leukocytes show an impaired response to most Toll-
like receptor (TLR) and IL-1R agonists tested (  1  –  12  ). Specifi  -
cally, the patients ’   whole blood cells or PBMCs do not respond 
to IL-1    , in terms of IL-6 secretion (  1  ), or to IL-18, in terms 
of IFN-     production (  1, 4  ). Moreover, agonists of TLR1/2 
(Pam  3  CSK  4  ), TLR2/6 (Pam  2  CSK  4  ), TLR3 (poly(I:C)), TLR4 
(LPS), TLR5 (fl  agellin), and TLR9 (CpG DNA), do not in-
duce the production of major infl  ammatory cytokines (TNF-    , 
IL-6, and IL-12) and growth factors (G-CSF and GM-CSF) 
in whole blood cells and PBMCs (  1  –  9, 11, 12  ). However, the 
patients  ’   PBMCs do respond to the nonspecifi  c TLR3 agonist 
poly(I:C) and the TLR4-specifi  c agonist LPS by producing 
IFN-     mRNA (for poly(I:C) and LPS) or IFN-     protein (for 
poly(I:C) only) (  13  ). Moreover, the patients  ’   fi  broblasts have 
been shown to respond to poly(I:C) by inducing IFN-    , IFN-    , 
and IL-6 (  13  ). The human IRAK-4  –  independent TLR3/4 
pathway is reminiscent of the mouse MyD88-independent, 
Toll/IL-1 receptor (TIR) domain  –  containing adaptor-inducing 
IFN-     (TRIF)  –  dependent TLR3/4 pathway (  14, 15  ), which 
also controls the induction of cytokines other than IFNs, at 
least for TLR3 (  16, 17  ). Despite the lack of IL-6 and TNF-     
induction in response to poly(I:C) in human IRAK-4  –  defi  cient 
whole blood cells (  1  ), the normal induction of IFN-    , -    , 
and -     in response to poly(I:C) and LPS (  13  ) raises the pos-
sibility that IRAK-4 defi  ciency may not prevent the induction 
of other cytokines in response to these two and possibly other 
TLR agonists. 
  The lack of response of IRAK-4  –  defi  cient whole blood 
cells and PBMCs to TLR and IL-1R agonists also does not 
exclude the possibility that individual leukocyte subsets may 
respond to at least some agonists. Several human leukocyte 
subsets produce TLR mRNAs and/or proteins. In the myeloid 
lineage, neutrophilic granulocytes express TLR1, 2, 4, 5, 6, 7, 8, 
and 10, as well as TLR9 upon induction with GM-CSF (  18  ); 
monocytes express TLR1, 2, 4, 5, 6, 7, 8, and 9 (  19  –  21  ); mye-
loid DCs (MDCs) express TLR1, 2, 3, 4, 5, 6, 7, 8, and 10 (  22  ); 
Human interleukin (IL) 1 receptor–associated kinase 4 (IRAK-4) defi  ciency is a recently discovered primary immuno-
defi  ciency that impairs Toll/IL-1R immunity, except for the Toll-like receptor (TLR) 3– and TLR4–interferon (IFN)- 
pathways. The clinical and immunological phenotype remains largely unknown. We diagnosed up to 28 patients with 
IRAK-4 defi  ciency, tested blood TLR responses for individual leukocyte subsets, and TLR responses for multiple cyto-
kines. The patients’ peripheral blood mononuclear cells (PBMCs) did not induce the 11 non-IFN cytokines tested upon 
activation with TLR agonists other than the nonspecifi  c TLR3 agonist poly(I:C). The patients’ individual cell subsets 
from both myeloid (granulocytes, monocytes, monocyte-derived dendritic cells [MDDCs], myeloid DCs [MDCs], and 
plasmacytoid DCs) and lymphoid (B, T, and NK cells) lineages did not respond to the TLR agonists that stimulated 
control cells, with the exception of residual responses to poly(I:C) and lipopolysaccharide in MDCs and MDDCs. Most 
patients (22 out of 28; 79%) suffered from invasive pneumococcal disease, which was often recurrent (13 out of 22; 
59%). Other infections were rare, with the exception of severe staphylococcal disease (9 out of 28; 32%). Almost half 
of the patients died (12 out of 28; 43%). No death and no invasive infection occurred in patients older than 8 and 14 yr, 
respectively. The IRAK-4–dependent TLRs and IL-1Rs are therefore vital for childhood immunity to pyogenic bacteria, 
particularly Streptococcus pneumoniae. Conversely, IRAK-4–dependent human TLRs appear to play a redundant role in 
protective immunity to most infections, at most limited to childhood immunity to some pyogenic bacteria.JEM VOL. 204, October 1, 2007 
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locus, and the genotyping of polymorphic markers showed that 
P2 was heterozygous for a large de novo deletion (designated 
BAC210N13del) encompassing   IRAK4   (Fig. S1, top, available 
at http://www.jem.org/cgi/content/full/jem.20070628/DC1; 
and not depicted). For P7, using the same BAC as for P2, 
fl  uorescence in situ hybridization revealed two signals, consistent 
with homozygosity owing to segmental uniparental disomy or 
compound heterozygosity with an undetected deletion encom-
passing a fraction of   IRAK4   (Fig. S1, bottom; and not depicted). 
Not enough material was available to explore the   IRAK4   
locus in the deceased patients P11 and 12 from kindred I (  8  ). 
3 out of the 14 mutant alleles identifi  ed carried nonsense 
mutations (Y48X, Q293X, and E402X) (  1, 3, 4, 6, 8, 9, 11, 36  ), 
3 carried large deletions ( 1-1096_4023del  ,  BAC210N13del  , 
and   942-1481_1125547del  ), 2 carried splice mutations 
(  1188520A  	  G   and   1189-1G  	  T  ) (  12  ), and 6 carried 
frameshift insertions and deletions (  167_172insA  ,   573delA  , 
  620_621delAC  ,   631delG  ,   821delT  , and   1240insA  ) (  1, 4, 7, 34  ) 
(  Table I   and   Fig. 2 A  ).   All mutations are predicted to be null, 
as they create a premature termination codon or delete a large 
segment of the gene. No missense mutation was found. The 14 
mutations were not found in 100 healthy controls sequenced. 
the clinical course of a large number of IRAK-4  –  defi  cient 
patients and testing the TLR responses of their PBMCs for 
multiple cytokines, as well as the TLR responses of their indi-
vidual leukocyte subsets. 
    RESULTS   
    IRAK4   mutations 
  We report 28 patients with IRAK-4 defi  ciency. The patients 
originate from 18 unrelated kindreds and 11 countries (  Table I   
and   Fig. 1  ).   All   IRAK4   exons, fl  anking intron regions, and, 
when appropriate, entire introns, were sequenced in 24 patients 
(P1  –  4, 6  –  13, 15, 17  –  20, and 22  –  28). IRAK-4 defi  ciency was 
diagnosed on clinical grounds in four deceased relatives (P5, 
14, 16, and 21) for whom no biological material was available. 
The patients of 13 kindreds were apparently homozygous 
(kindreds A  –  C, E, F, H  –  L, and P  –  R), and those from 5 kindreds 
were compound heterozygous (D, G, and M  –  O) for   IRAK4   
mutations. However, four seemingly homozygous patients 
from three unrelated families (P2 from kindred B, P7 from 
kindred F, and P11 and 12 from kindred I) had one parent 
who did not carry the mutant allele. Fluorescence in situ 
hybridization with BAC210N13, which covers the entire  IRAK4   
  Figure 1.     Pedigree of the 18 kindreds identifi  ed with IRAK-4 defi  ciency. Each kindred is designated by a capital letter (A  –  R), each generation is 
designated by a Roman numeral (I  –  IV), and each individual is designated by an Arabic numeral (from left to right). IRAK-4  –  defi  cient patients with a clini-
cal phenotype are represented as closed symbols. P20, the only patient with confi  rmed IRAK-4 defi  ciency but no known clinical phenotype, is represented 
with an open square divided by a black line. In each family, the proband is indicated by an arrow. Individuals whose genetic status could not be evaluated 
are indicated by   “  E?  ”  ; they include four individuals (P5, 14, 16, and 21) thought to be IRAK-4 defi  cient based on their clinical phenotypes.     2410 IRAK-4 DEFICIENCY | Ku et al.
Q293X), P8 (mutations   1188+520A  	  G   and   1189-1G  	  T  ), P13 
(mutation E402X), P19 (mutation   167_172insA  ), and P22 
(mutation Q293X/  620-621del  ) had low levels of detectable 
full-length   IRAK4   mRNA. We then assessed IRAK-4 protein 
levels in B-EBVs (  Fig. 2 C  ). No IRAK-4 protein was detected 
in any of the patients tested, even in P7, 8, 13, 19, and 22, 
all of whom had detectable full-length mRNAs, excluding 
a potential role of IRAK-4 as a scaff  old protein in our 
patients (  40, 41  ). Finally, we assessed the functional impact of 
  IRAK4   mutations. B-EBVs bearing mutations   821delT   (P1), 
Q293X (P2, 3, and 7),   1188520A  	  G/1189-1G  	  T   (P8), 
E402X (P13), and   1-1096_4023del   (P15) did not respond 
to TLR7 and 8 agonists, as measured by TNF-     production 
(  Fig. 3 A  ).   SV40-transformed fi  broblasts (SV40-fi  broblasts) 
The Q293X mutant allele was found in homozygotes from 
six kindreds (C, H, K, P, Q, and R) and compound hetero-
zygotes from four kindreds (B, D, M, and possibly F). The 
recurrence of this mutation may refl  ect a mutational hotspot, 
a founder eff  ect, or both (unpublished data). 
  IRAK-4 expression and function 
  We assessed   IRAK4   mRNA levels in EBV-transformed B 
lymphocyte cell lines (B-EBVs;   Fig. 2 B  ) derived from most 
patients and a healthy control by RT-PCR. The two patients 
carrying the   573delA   mutation died before cell lines could be 
established (  34  ). Most other patients lacked detectable full-
length   IRAK4   mRNAs species, presumably because of non-
sense-mediated mRNA degradation. However, P7 (mutation 
    Table I.        Genotypes, origin, and clinical phenotypes of IRAK-4  –  defi  cient patients 
Kindred Patient Mutation Origin Follow-up Age Pathogens causing  
  severe Gram-positive  
  infections
Pathogens causing  
  severe Gram-negative  
  infections
References
A P1 (II-4)   821delT  KSA deceased 7 yr Sp, Sa   – (  1, 13  )
B P2 (II-2) Q293X  /  
 BAC210N13del 
Portugal alive 14 yr Sp, Sa   – (  1, 10, 13  )
C P3 (II-1) Q293X USA alive 11 yr Sp, Sa Ec (  1, 3, 33  )
D P4 (II-1) Q293X  /  
 620-621delAC 
USA alive 24 yr Sp, Cs Nm (  2, 4, 35  )
E P5 (II-1) ND Turkey deceased 16 mo Sp, Spa   – (  34  )
E P6 (II-4)   573delA Turkey deceased 2  mo Sp   – (  34  )
F P7 (II-2) Q293X UK alive 32 yr Sp Ss (  6, 10, 13  )
G P8 (II-1)   1188520A  	 G/   
 1189-1G 	 T  
Hungary alive 9 yr Sp   – (  10, 12, 13  )
H P9 (II-1) Q293X Canada deceased 6 yr Sp Pa (  5, 9, 13  )
H P10 (II-4) Q293X Canada alive 7 yr Sp   – (  5, 9, 13  )
I P11 (III-1) E402X Spain deceased 2 yr Sa Pa (  8, 13  )
I P12 (III-4) E402X Spain deceased 8 mo Sp Pa (  8, 13  )
I P13 (IV-1) E402X Spain alive 9 yr Sp   – (  8, 10, 13  )
J P14 (II-2) ND Israel deceased 3 mo Sm   – (  13  )
J P15 (II-3)   1-1096_4023del  Israel alive 9 yr Sp   – (  10, 13  )
K P16 (II-1) ND Canada deceased 5 mo Sa   – (  13, 36  )
K P17 (II-2) Q293X Canada alive 27 yr Sp Pa (  13, 36  )
K P18 (II-3) Q293X Canada alive 27 yr Sp   – (  13, 36  )
L P19 (II-1)   167_172insA Japan deceased 2  yr Sp   – (  7  )
L P20 (II-2)   167_172insA Japan alive 24  mo   –   – (  7) 
M P21 (II-2) ND USA deceased 4 mo bacterial meningitis   – this  study
M P22 (II-3) Q293X  /  
 620-621delAC 
USA alive 10 yr Sp, Sa   – this  study
N P23 (II-1) Y48X  /  
 631delG 
Canada alive 2 yr Sa   – this  study
O P24 (II-1)   1240insA/  
   942-1481_1125547del 
Canada alive 16 yr Sp, Sa   – this  study
P P25 (II-1) Q293X Australia deceased 4 mo Sp   – this  study
P P25 (II-5) Q293X Australia deceased 6 mo Sp, Sa   – this  study
Q P27 (II-2) Q293X USA alive 11 yr Sp   – this  study
R P28 (II-1) Q293X USA alive 6 yr Sp   – (  11 )
Cs,   Clostridium septicum  ; Ec,   E. coli  ; KSA, Kingdom of Saudi Arabia; Nm,   N. meningitidis ;  Pa,   P. aeruginosa  ; Sa,   S. aureus  ; Sm,   S. milleri  ; Sp,   S. pneumoniae  ; Spa,   S. parasanguis ; 
Ss,   S. sonnei .JEM VOL. 204, October 1, 2007 
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IgG levels were normal in seven and high in four (P7, 8, 11, 
and 17) patients, and IgM levels were normal in seven, high in 
three (P7, 11, and 19), and low in one (P2) patients. IgE levels 
were high in 8 (P1, 7, 8, 11, 13, 15, 17, and 23) out of the 
11 patients evaluated (Table S2). Antibody responses to protein 
antigens were normal in all but two patients, who had slightly 
low titers (P7 and 15); however, the date of recall vaccination 
before serological testing was unknown. The antibody response 
to glycans was impaired in some (P2, 8, 17, 18, and 29) but not 
all patients, and in response to some but not all pneumococcal 
and erythrocyte AB antigens (Table S2 and unpublished data) 
(  11, 12, 33  ). Finally, the surface expression of CD16 and CD56 
on NK cells was normal (Table S1). IFN-     secretion and sur-
face expression of CD107 (degranulation) by the patients  ’  NK 
cells were normal (unpublished data). Overall, there seemed 
to be no overt defect of leukocyte development in IRAK-4  –
  defi  cient patients. Thus, antigen-specifi  c T and B cell responses 
seemed to be normal, except for an impaired glycan-specifi  c 
antibody response in at least some patients and against some 
glycans, and except for an overproduction of IgE in most of 
the patients tested. 
  Impaired production of multiple cytokines by blood 
mononuclear leukocytes 
  We previously reported that IRAK-4  –  defi  cient whole blood 
cells and PBMCs produce only very small amounts of TNF-    , 
bearing mutations   821delT   (P1), Q293X (P2 and 3),     1188
520A  	  G/1189-1G  	  T       (P8), E402X (PI3),     1-1096_4023del   
(P15), Y48X/ 631delG   (P23), and   1240insA/942-1481_1125
547del   (P24) did not respond to IL-1    , as assessed by measur-
ing IL-6 production. However, IRAK-4  –  defi  cient SV40-
  fi  broblasts did produce IL-6 upon activation by poly(I:C) 
(  Fig. 3 B  ) (  13  ). Thus, all patients had complete IRAK-4 defi  -
ciency and a complete absence of IRAK-4  –  dependent TIR 
signaling, owing to the inheritance of two loss-of-expression, 
loss-of-function   IRAK4   alleles. 
  Development and function of blood leukocyte subsets 
  We analyzed blood leukocyte subsets in 12 IRAK-4  –  defi  cient 
patients. We previously showed that granulocytes, CD14    , 
CD16    , and CD14    /CD16     monocyte subsets, and MDCs and 
PDCs, were present in normal numbers in three patients (  13  ). 
We now report that T cell subsets, including CD4     and CD8    , 
and CD45RA     and CD45RO     T cells, are also present in nor-
mal numbers (Table S1, available at http://www.jem.org/cgi/
content/full/jem.20070628/DC1), with the possible exception 
of normal to low levels of T cells in P17 and 18 (  36  ). T cells 
proliferated normally in response to the mitogen PHA, CD3, 
and recall antigens in vitro (Table S2). B cells and memory B 
cells (CD27    ) were also present in normal numbers (Table S1). 
Serum Ig levels for IgA were normal in fi  ve, high in two 
(P8 and 11), and low in four (P1, 2, 17, and 18) patients (  36  ). 
  Figure 2.     IRAK-4 defi  ciency. (A) Schematic representation of   IRAK4   with all identifi  ed mutations. The gene is composed of 12 exons, with exon 1 and 
a part of exon 12 noncoding. The N-terminal death domain (DD) and C-terminal kinase domain (KD) are shown in light gray. (B) RT-PCR of the full-length 
  IRAK4   and   GAPDH   genes in B-EBVs from a healthy control (C) and nine IRAK-4  –  defi  cient patients. (C) IRAK-4 and GAPDH protein levels in B-EBVs from a 
healthy control and nine IRAK-4  –  defi  cient patients, as shown by Western blotting. White lines indicate that intervening lanes have been spliced out.     2412 IRAK-4 DEFICIENCY | Ku et al.
at http://www.jem.org/cgi/content/full/jem.20070628/DC1). 
IL-7 induction was abolished in the patients, whereas other 
cytokines were not induced in controls. The patients ’   PBMCs 
showed detectable IL-8 and MIP-1     (an IFN-inducible 
cytokine) responses to LPS, but these responses were weaker 
than those of healthy controls (  Fig. 4  ). The other cytokines 
were not induced in the patients. These data are reminiscent 
of our previous observation that IRAK-4  –  defi  cient PBMCs 
respond to poly(I:C) by producing IFN-     protein, and to 
poly(I:C) and LPS by producing IFN-     mRNA (  13  ). How-
ever, whereas LPS responses can be specifi  cally ascribed to 
TLR4, we recently showed, in TLR3-defi  cient patients, that 
the poly(I:C) responses of PBMCs are TLR3-independent 
(  42  ). These data indicate a broad immunological impact of 
IRAK-4 defi  ciency, as the production of 11 key cytokines 
was completely impaired in response to all TLR agonists, 
with the exception of a couple of cytokines in response to 
poly(I:C) and LPS. 
  TLR responses of individual myeloid subsets 
  We then assessed the role of IRAK-4 in TLR signaling path-
ways in discrete leukocyte cell populations. Cell subsets other 
IL-6, IL-12, G-CSF, GM-CSF, and IFN-     in vitro in response 
to all IL-1R and TLR agonists tested (  1  –  9, 11, 12  ). We won-
dered whether the induction of other cytokines, chemokines, 
IFNs, and growth factors was also dependent on IRAK-4 
  after TLR stimulation. We therefore activated PBMCs from 
IRAK-4  –  defi   cient patients with Pam  3  CSK  4   (TLR1/2), 
Pam  2  CSK  4   (TLR2/6), poly(I:C) (a nonspecifi  c TLR3 agonist), 
LPS (TLR4), fl  agellin (TLR5), 3M-13 (TLR7), 3M-2 (TLR8), 
R-848 (TLR7 and 8), and CpG (TLR9) for 24 h. We did 
not assess TLR10 responses, as there is no known agonist for 
this receptor (  23  ). Cytokine secretion into the supernatant 
was assessed using a multiplex cytometry-based system. 11 out 
of the 25 cytokines assayed were induced and detectable 
after TLR stimulation in healthy controls. IRAK-4  –  defi  cient 
cells did not respond to seven out of nine agonists for all 
cytokines tested (  Fig. 4  ).   Upon activation with poly(I:C), the 
patients  ’   PBMCs displayed induction of IL-12, monocyte 
chemoattractant protein 1, and macrophage infl  ammatory 
protein 1     (MIP-1    ) to levels similar to those in healthy 
controls, as well as some induction of IFN-inducible protein 
10 (  Fig. 4  ). However, the induction of IL-12 and MIP-1     was 
weak in both patients and healthy controls (Fig. S2, available 
  Figure 3.     Impaired cellular responses to TIR agonists in IRAK-4  –  defi  cient cell lines. (A) TNF-     production by B-EBVs from a healthy control (C) 
and seven IRAK-4  –  defi  cient patients 24 h after stimulation with various TLR agonists and PMA/ionomycin. (B) IL-6 production by SV40-fi  broblasts from a 
healthy control and eight IRAK-4  –  defi  cient patients after 24 h of stimulation with IL-1   ,  TNF-   , poly(I:C), and PMA/ionomycin. Mean values and SDs are 
shown for triplicates of a single experiment.     JEM VOL. 204, October 1, 2007 
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IFN-inducible surface-expressed CD40, CD80, and CD86 
by in vitro MDDCs, which respond to poly(I:C) in a TLR3-
dependent manner (  42  ). MDDCs from healthy controls re-
sponded normally to the TLR agonists Pam  3  CSK  4  , Pam  2  CSK  4  , 
poly(I:C), LPS, fl  agellin, and 3M-2. In contrast, the patients  ’   
MDDCs did not respond to Pam  3  CSK  4  , Pam  2  CSK  4  , fl  agellin, 
and 3M-2. However, IRAK-4  –  defi  cient MDDCs showed 
a weak but not abolished TNF-     response and normal 
induction of CD40, CD80, and CD86 upon activation with 
poly(I:C) (TLR3). Normal induction of CD40, CD80, and 
CD86 was also observed upon activation with LPS (TLR4) 
(  Fig. 5, G and H  ). These data indicate that the IRAK-4  –
  defi  cient individual myeloid cell subsets tested displayed no 
response to most TLR agonists, with the exception of nor-
mal responses to poly(I:C) and LPS detected in MDCs for 
MIP-1    , an IFN type I  –  inducible cytokine, and in MDDCs 
for CD40, CD80, and CD86, which are induced by type I IFNs 
and TNF-    . 
  TLR responses of individual lymphoid subsets 
  We then tested the TLR responses of the B, T, and NK lym-
phoid cell subsets. The subsets were purifi  ed by cell sorting 
(purity   	  99.5%). CD19     B cells were activated by incubation 
with the TLR agonists Pam  3  CSK  4  , Pam  2  CSK  4  , poly(I:C), LPS, 
fl  agellin, 3M-13, 3M-2, R-848, and CpG for 24 h, and their 
response was measured by assessing IL-10 production. Highly 
purifi  ed control B cells showed a unique pattern of activation, 
with no response to agonists of TLR1/2, TLR2/6, TLR3, TLR4, 
TLR5, and TLR8, and only weak IL-10 production in response 
to TLR7, TLR7 and TLR8, and TLR9 agonists (  Fig. 6 A   and 
not depicted).   In contrast, no response to these TLR agonists 
than granulocytes and DCs were purified by cell sorting 
(purity   	  99.5%). More than 95% of the granulocytes purifi  ed on 
Ficoll were CD15  +  . The response of DCs (MDCs and PDCs) 
was tested in PBMCs. We assessed the CD62L shedding of 
granulocytes from four healthy controls and four IRAK-4  –
  defi  cient patients after activation with Pam  3  CSK  4  , Pam  2  CSK  4  , 
LPS, fl  agellin, 3M-13, 3M-2, R-848, and TNF-     (  10  ). The 
response to all TLR agonists was impaired in the granulo-
cytes of all four patients tested (  Fig. 5 A  ).   CD14     monocytes 
from healthy controls responded to TLR1  –  8 agonists but not 
to TLR9 agonists. The monocytes of IRAK-4  –  defi  cient patients 
did not respond to these agonists, with the possible exception 
of very weak TNF-     production upon LPS stimulation 
(  Fig. 5 B  ). Finally, we tested MDCs and PDCs by stimulating 
PBMCs from seven healthy donors and three IRAK-4  –  defi  -
cient patients with the TLR agonists Pam  3  CSK  4  , Pam  2  CSK  4  , 
poly(I:C), LPS, fl  agellin, 3M-13, 3M-2, R-848, and CpG 
for 3 h. We assessed TNF-     and MIP-1     production for 
MDCs (Lin-1    −   , HLA-DR    , and CD123  low  ) and PDCs (Lin-1    −   , 
HLA-DR    , and CD123  high  ) by intracellular staining. In healthy 
individuals, MDCs responded to all of the TLR agonists 
tested, except the TLR9 agonist, with the induction of TNF-     
and MIP1-    . In contrast, only upon activation with poly(I:C) 
(nonspecifi  c TLR3 agonist) and LPS (TLR4), did MDCs 
from the patients display normal levels of MIP1-     induction 
and some induction of TNF-    . PDCs from healthy individ-
uals responded only to agonists of TLR7 and 9, whereas 
IRAK-4  –  defi  cient PDCs did not respond to any of the ago-
nists tested (  Fig. 5, C  –  F  ). As poly(I:C) activation in MDCs 
appears to be TLR3 independent (  42  ), we further evalu-
ated the production of TNF-     and the up-regulation of 
  Figure 4.     Multiple cytokine secretion in IRAK-4  –  defi  cient PBMCs. PBMCs from three healthy controls and three IRAK-4  –  defi  cient patients (P17, 
18, and 22) were activated with various TLR agonists for 24 h. Cytokine levels are represented as ratios of the mean secretion observed in the three IRAK-4  – 
defi  cient patients to that in three healthy controls. Cytokines represented in gray are not induced upon the stimulation of control PBMCs.     2414 IRAK-4 DEFICIENCY | Ku et al.JEM VOL. 204, October 1, 2007 
ARTICLE
2415
the age of 2 yr (20 out of 28; 71%), often before the age of 
6 mo (9 out of 28; 32%) and in the neonatal period (4 out 
of 28; 14%), when maternal antibodies are still present. 
Remarkably, no invasive infection was documented in the 
six patients over the age of 14 yr (P2, 14 yr; P4, 24 yr; P7, 32 yr; 
P17 and 18, 27 yr; and P24, 16 yr), even in the absence of 
prophylaxis (P2, 4, 7, 17, and 18;   n   = 5;   Fig. 7 A  ) (  4, 6, 36  ).   
12 patients died of invasive Gram-positive infections, all be-
fore the age of 8 yr and most before the age of 2 yr (  Fig. 7 B  ). 
IRAK-4 defi  ciency is thus associated with a selective predis-
position to pyogenic bacterial infections, mostly caused by 
Gram-positive bacteria (  S. pneumoniae   in particular and   S. aureus   
to a lesser extent), and clinical status and outcome both 
improve with age. The detailed clinical features of IRAK-4 
defi  ciency will be reported elsewhere (unpublished data). 
    DISCUSSION   
  The 28 patients reported in this study suff  ered from complete 
IRAK-4 defi  ciency. The patients had been exposed to an 
extremely diverse range of microorganisms, including many 
potential viral, bacterial, and fungal pathogens, as well as par-
asites (Tables S2 and S3, available at http://www.jem.org/cgi/
content/full/jem.20070628/DC1). However, IRAK-4  –  defi  -
cient patients presented a strikingly narrow infectious pheno-
type (  Table I  ), similar to the three patients initially reported (  1  ). 
27 patients suff  ered from invasive infectious disease, typically 
caused by Gram-positive   S. pneumoniae   (  n   
 22; 79%) and/or 
  S. aureus   (  n   
 9; 32%). Seven patients (25%) also presented 
severe infections with Gram-negative bacteria (  P. aeruginosa  , 
  N. meningitidis  ,   S. sonnei  , and   S. marcescens  ). 15 patients had 
peripheral infectious disease. When identifi  ed, the causal patho-
gens were   S. aureus  ,   P. aeruginosa  , and   Streptococcus   species. 
The susceptibility of IRAK-4  –  defi  cient patients to   S. aureus   
is consistent with that observed in IRAK-4  –   and MyD88-
defi  cient mice (  31, 43  ). MyD88-defi  cient mice are suscepti-
ble to   P. aeruginosa   (  44  ) and, in some models, to   S. pneumoniae   
(  45, 46  ). Intriguingly, the 28 IRAK-4  –  defi  cient patients were 
not particularly susceptible to most other microorganisms, 
including common viruses (e.g., herpes viruses, enteroviruses, 
adenoviruses, and papillomaviruses), and widespread bacteria 
(e.g.,   Listeria  ,   Mycobacterium  , and Enterobacteriaceae), parasites 
(e.g.,   Toxoplasma  ), and fungi (e.g.,   Cryptococcus  ,   Pneumocystis  , 
  Candida  , and   Aspergillus  ). As fi  ve of these patients have had 
was observed in the three IRAK-4  –  defi  cient patients tested 
(  Fig. 6 A  ). Moreover, the response to TLR7 and 9, as measured 
by cell-surface expression of CD40, CD80, and CD86 after 3 d 
of incubation with IL-4 and various TLR agonists, was also im-
paired in the patients  ’   B cells (  Fig. 6 B  ) (  13  ). CD3  +   T cells from 
healthy individuals were activated by Pam  3  CSK  4  , Pam  2  CSK  4  , 
poly(I:C), LPS, fl   agellin, 3M-13, 3M-2, R-848, and CpG. 
Control T cells displayed a weak but detectable response to 
Pam  3  CSK  4   and fl  agellin in terms of IFN-     production, whereas 
T cells from IRAK-4  –  defi  cient patients were not activated by 
any of the TLR agonists (  Fig. 6 C  ). Finally, control NK cells 
were shown to respond to TLR3, 7, and TLR7 and 8 agonists 
in terms of IFN-     production, but no response was observed 
in NK cells from IRAK-4  –  defi  cient patients (  Fig. 6 D  ). NK cells 
respond to poly(I:C) through TLR3 (  42  ), suggesting that at 
least some TLR3 pathways are IRAK-4 dependent. These 
data indicate that the three major blood lymphoid subsets re-
quire IRAK-4 for TLR responses, including TLR3 responses 
in NK cells. 
  Clinical features of IRAK-4 defi  ciency 
  In total, 28 IRAK-4  –  defi  cient patients from 18 families were 
studied, including the 7 patients (P21  –  27) from 5 families de-
scribed in this study for the fi  rst time (  Table I   and   Fig. 1  ). 
Most IRAK-4  –  defi  cient patients had had at least one Gram-
positive bacterial infection: 22 out of the 28 (79%) had had 
invasive disease caused by   S. pneumoniae   (meningitis, septicemia, 
or arthritis), and 9 out of the 28 (32%) had suff  ered severe 
disease caused by   S. aureus   (meningitis, septicemia, or liver 
abscess;   Table I  ). If we also take into account peripheral 
staphylococcal disease (cellulitis and subcutaneous abscess), 
14 patients could be considered particularly susceptible to 
  S. aureus  . One patient (P20) had had no major infectious 
disease. This patient is 25 mo old and was diagnosed with 
IRAK-4 defi  ciency as a neonate. He was placed on IgG sub-
stitution and antibiotic prophylaxis shortly after birth. Seven 
patients also suff  ered from severe Gram-negative bacterial 
infections, which were invasive in four cases (  Shigella sonnei   
and   P. aeruginosa  ) and peripheral in four cases (  Escherichia coli  , 
  Serratia marcescens  ,   Neisseria meningitidis  , and   P. aeruginosa  ). As 
previously reported in a smaller series (  13  ), no severe viral, 
fungal, or parasitic infections were observed in the patients. 
Most patients developed their fi  rst invasive infection before 
  Figure 5.     Impaired responses to TLR agonists in IRAK-4  –  defi  cient individual myeloid subsets. (A) Cleavage of CD62 ligand (CD62L) at the surface 
of granulocytes from a healthy control and an IRAK-4  –  defi  cient patient (P7) after activation for 1 h with various TLR agonists and TNF-    . The black line 
shows CD62L expression on nonactivated granulocytes, and the red line shows CD62L expression after 1 h of activation with various agonists (induced 
CD62L shedding). One experiment representative of four (P7, 8, 13, and 15) is shown. (B) TNF-     secretion by CD14     monocytes after 24 h of activation 
with various TLR agonists. Mean values and SDs were calculated from four healthy controls and three IRAK-4  –  defi  cient patients. (C  –  F) Ex vivo MDC and 
PDC responses. PBMCs from healthy controls and IRAK-4  –  defi  cient patients were stimulated with various TLR agonists. In both subsets, responses were 
measured by staining for intracellular TNF-     (C) and MIP-1     (E). Mean values and SDs were calculated from six different controls and four IRAK-4  –  defi  -
cient patients for TNF-     (D), and from seven different controls and three IRAK-4  –  defi  cient patients for MIP-1     (F). (G) TNF-     secretion in vitro by MDDCs 
after 24 h of activation. Means and SDs were calculated from six different controls and three different IRAK-4  –  defi  cient patients. (H) Induction of CD40, 
CD80, and CD86 surface expression on MDDCs from a control (top) and an IRAK-4  –  defi  cient patient (bottom) after 24 h of stimulation with various TLR 
agonists. Black and green lines indicate the expression of CD40, CD80, and CD86 without and after stimulation, respectively. The experiment shown is 
representative of three independent experiments (also performed on patients P15 and 18). C, control.     
 2416 IRAK-4 DEFICIENCY | Ku et al.
  Listeria monocytogenes   (  49, 50  ),   Mycobacterium avium   (  51  ), 
  Toxoplasma gondii   (  52  ),   Cryptococcus neoformans   (  53  ),   Candida 
albicans  , and   Aspergillus fumigatus   (  54  ), among other relevant 
infections (  37  –  39  ). 
  So why are the infectious phenotypes of MyD88/IRAK-
4  –  defi  cient mice and IRAK-4  –  defi  cient humans so diff  erent? 
An overrepresentation of MyD88 defi  ciency with respect 
to IRAK-4 defi  ciency in mouse studies may be involved, 
no prophylaxis for 60 patient years (  Fig. 7 B  ) (  4, 6, 36  ), the 
resistance to most microbes observed is unlikely to be caused 
by the early death of some patients or to the prophylactic 
treatment of the survivors. Ascertainment bias cannot be ex-
cluded, but remains unlikely, as 10 aff  ected relatives with 
causal mutations shared the case-defi  nition clinical pheno-
type of index cases. In contrast, MyD88-defi  cient mice were 
found to be susceptible to mouse CMV (  47  ), HSV-1(  48  ), 
  Figure 6.     Lack of response to TLR agonists of individual IRAK-4  –  defi  cient lymphoid subsets. (A) IL-10 secretion by CD19     B cells after 24 h of 
activation with various TLR agonists and PMA/ionomycin. Mean values      SD were calculated from the data obtained for three different controls and three 
IRAK-4 – defi  cient patients. (B) Induction of CD40, CD80, and CD86 surface expression on CD19     B cells after activation for 72 h with 3M-13 and CpG. 
Black and green lines indicate the expression of CD40, CD80, and CD86 without and after stimulation, respectively. Data are representative of two inde-
pendent experiments. (C) IFN-     secretion by CD3     T cells after stimulation for 24 h with various TLR agonists and anti-CD3 (50 ng/ml OKT3) antibody in 
the presence of 100 U/ml IL-2 for 2 d. Mean values      SD were calculated for three different controls and two IRAK-4  –  defi  cient patients. (D) IFN-     secre-
tion by CD3      /CD56    NK cells after activation for 24 h with various TLR agonists and PMA/ionomycin. Mean values and SDs were calculated for three 
different controls and three IRAK-4  –  defi   cient  patients.   JEM VOL. 204, October 1, 2007 
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  We further excluded the possibility that human IRAK-4 
defi  ciency may be milder than mouse MyD88/IRAK-4 defi  -
ciency owing to the occurrence of human-specifi  c IRAK-4  –
  independent TLR pathways in discrete leukocyte subsets, as 
suggested by the normal induction of both IL-6 and IFN-    /     in 
IRAK-4  –  defi  cient fi  broblasts (  13  ). We showed that IRAK-4 
defi  ciency impaired the TLR responses of all lymphoid and 
myeloid leukocyte subsets tested ex vivo, including granulo-
cytes, monocytes, PDCs, MDCs, NK, T, and B cells. With 
the exception of the induction of IFN-inducible MIP-1     pro-
duction in MDCs in response to poly(I:C) and LPS (  Fig. 5, 
E and F  ), there was no detectable TLR response in individual 
subsets. The LPS response is TLR4 dependent, whereas the 
poly(I:C) response in MDCs appears to be TLR3 independent 
(  42  ). Even IRAK-4  –  defi  cient NK cells did not respond to 
poly(I:C), suggesting that responses to poly(I:C) in NK cells 
are largely TLR3- (  42  ) and IRAK-4  –  dependent. Moreover, 
MDDCs generated in vitro did not respond to TLR agonists, 
with the exception of poly(I:C) and LPS. The poly(I:C)-trig-
gered induction of TNF-    , CD40, CD80, and CD86 in 
MDDCs was IRAK-4 independent (  Fig. 5, G and H  ) and 
seemed to be TLR3 dependent (  42  ). These data extend previous 
fi  ndings (  1, 13  ) and show that human IRAK-4 plays a non-
redundant role in the conventional TLR signaling pathway in at 
least seven major leukocyte subsets. In contrast, IRAK-4 may 
be dispensable for the   “  alternative,  ”   TRIF-dependent pathways 
downstream from TLR3 (for IFNs and other cytokines) and 
  although IRAK-4  –   and MyD88-defi  cient mice, when infected 
by the same pathogens, are indistinguishable (  31, 43  ). We pro-
vide an experimental demonstration in this paper that the 
occurrence of human-specifi  c IRAK-4  –  independent TLR 
pathways is not involved. We show that IRAK-4  –  defi  cient 
PBMCs do not secrete any of 11 cytokines tested when stim-
ulated with agonists of TLR1, 2, 5, 6, 7, 8, and 9. The TLR4 
response was abolished for all but two cytokines, which 
were weakly induced. One of these two cytokines was the 
IFN-inducible MIP-1    , consistent with the IFN-     mRNA 
response to LPS in IRAK-4  –  defi  cient PBMCs (  13  ). IRAK-4  –
  defi  cient PBMCs also responded to poly(I:C), producing 
IFN-inducible monocyte chemoattractant protein 1 and IFN-
inducible protein 10, as expected from the previously re-
ported induction of IFN-    , -    , and -     in IRAK-4  –  defi  cient 
PBMCs and fi  broblasts (  13  ). However, poly(I:C) activates 
PBMCs normally in patients with TLR3 defi  ciency (  42  ), 
making it diffi   cult to infer conclusions about TLR3 responses 
from the data for poly(I:C) stimulation. In any event, the 
MyD88- and IRAK-4  –  independent TLR3 and TLR4 path-
ways, present in mice, cannot account for humans being more 
resistant (  13, 15  ). The   “  conventional  ”   MyD88-dependent path-
way downstream from TLRs appears to be strictly IRAK-4  –
  dependent in humans; no detectable leakiness can apparently 
account for the narrow infectious phenotype. We cannot, 
however, exclude the possibility that other TLR-inducible 
genes may be IRAK-4 independent. 
  Figure 7.     Epidemiological features of IRAK-4 defi  ciency. (A) Incidence of invasive infections in IRAK-4  –  defi  cient patients during the fi  rst 40 mo 
of life (left) and the fi  rst 40 yr of life (right). Invasive infections included meningitis, septicemia, and arthritis. (B) Survival curve of 28 IRAK-4 – defi  cient 
patients during the fi  rst 40 mo of life (left) and the fi  rst 40 yr of life (right).     2418 IRAK-4 DEFICIENCY | Ku et al.
delayed acute infl  ammatory responses in vivo (low serum CrP 
levels in particular) (  34, 71  ). As CrP contributes to the clearance 
of   S. pneumoniae   (  72, 73  ), susceptibility to   S. pneumoniae   may 
be enhanced by the delayed increase in CrP levels. The con-
tribution of individual molecules upstream or downstream 
from IRAK-4 to infectious phenotypes should be clarifi  ed by 
the identifi  cation of new patients with mutations in the cor-
responding genes (  74  ). 
  Despite conferring selective susceptibility to only a few 
bacteria, IRAK-4 defi  ciency is life-threatening in infancy and 
childhood, with a mortality rate of 43% in our series. Most, if 
not all, patients would have probably died in the absence of 
antibiotic treatment. Strikingly, although IRAK-4 is abso-
lutely vital in childhood, infections become rarer with age, 
with no deaths recorded after the age of 8 yr and no invasive 
infection after the age of 14 yr, even in the absence of antibi-
otic or IgG prophylaxis for more than 60 patient years (  4, 6, 36  ). 
This dramatic improvement with age may be accounted for 
by the modest impact, if any, of IRAK-4 defi  ciency on anti-
gen-specifi  c T and B lymphocyte responses. Human T cells 
do not need IRAK-4 for activation by OKT3 in vitro (Table 
S2), in contrast to the results obtained for mice in a previous 
report (  32  ) and in accordance with a more recent study (  75  ). 
Moreover, our patients displayed no detectable global defect 
of protein antigen  –  specifi  c T and B cell responses. However, 
most of the patients displayed IgE overproduction, and some 
patients have been shown to have weak antibody responses 
to a subset of glycan antigens (  11, 12, 33  ). A more thorough 
investigation of B cells and antibody responses in IRAK-4  –
  defi  cient patients is therefore currently underway (unpub-
lished data). Our data are consistent with the apparently intact 
primary and secondary antigen-specifi  c responses in mice 
with MyD88 defi  ciency, TRIF defi  ciency, or both (  76, 77  ). 
Adaptive immunity may therefore progressively compensate 
for the poor innate immunity in our patients. An alternative 
and complementary hypothesis, accounting for the clinical 
improvement of IRAK-4  –  defi  cient patients with age, is that 
innate immune responses may also mature with age (  78, 79  ). 
As shown in this study, the TIR pathway, including TLR 
responses in particular, remains dependent on IRAK-4 with 
age, but the maturation of other innate pathways may gradu-
ally compensate for the lack of TIR  –  IRAK-4 signaling. 
  MATERIALS AND METHODS 
  Subjects and kindreds.     Our study was conducted according to the princi-
ples expressed in the Helsinki Declaration, with informed consent obtained 
from each patient or the patient  ’  s family. The study was approved by the 
Comit  é   d  ’    É  thique, CCPPRB, H  ô  pital Necker  –  Enfants Malades. 
  Molecular genetics.     Genomic DNA was isolated from whole blood cells 
or from B-EBVs. The cells were lysed by incubation overnight at 37  °  C in 
extraction buff  er (10 mM Tris, 0.1 M EDTA, 0.5% SDS, 1 mg/ml proteinase K) 
and subjected to phenol/chloroform extraction. DNA was precipitated 
in ethanol. Amplifi  ed PCR products were analyzed by electrophoresis in a 
1% agarose gel purifi  ed by centrifugation through superfi  ne resin (Sephadex 
G-50; GE Healthcare), sequenced by dideoxynucleotide termination with 
the BigDye terminator kit (Applied Biosystems), and analyzed on an ABI 
Prism 3730 apparatus (Applied Biosystems). 
TLR4 (for IFNs). Obviously, we cannot formally exclude the 
possibility that specifi  c leukocyte subsets in certain tissues (  55  ) 
and nonleukocyte cell types (  56  –  59  ) display IRAK-4  – 
independent TLR responses involved in host defense. 
  There are, therefore, no overt immunological diff  erences 
between MyD88/IRAK-4  –  defi  cient mice and IRAK-4–
  defi  cient patients. Nonetheless, MyD88 and IRAK-4 are criti-
cal for protective immunity to numerous pathogens in the 
mouse, whereas IRAK-4 is largely redundant for protective 
immunity in humans. Intrinsic diff  erences between mice 
and humans, aff  ecting receptors other than TLRs, may ac-
count for the observed discrepancies. There may be non-
TLRs governing the innate immune recognition of pathogens 
in humans but not in mice. An alternative, complementary 
hypothesis is that immunity to infection in animals is studied 
in experimental conditions, whereas immunity to infection 
in humans operates in natural conditions, accounting for 
considerable diff  erences in the hosts, microbes, and routes of 
infection (  60, 61  ). The human model can be used to defi  ne 
the function of host genes in a natural ecosystem in which 
species live and undergo selection. The ecologically relevant 
and evolutionarily selected function of human   IRAK4   ap-
pears to be narrower than predicted from experimental stud-
ies in the mouse. This is reminiscent of the narrow infectious 
phenotype of patients with mycobacterial disease and muta-
tions in the IL-12  –  IFN-     circuit (  62  ), or patients with herpes 
simplex encephalitis and mutations in the TLR3  –  UNC-93B 
pathway (  42, 63  ). In any event, whether owing to species 
diff  erences or to the conditions of infection, our fi  ndings for 
this series of IRAK-4  –  defi  cient patients strongly suggest that 
human IRAK-4–dependent TLRs are redundant for protec-
tive immunity to most microbes. 
  IRAK-4 seems to be crucial for protective immunity to 
Gram-positive   S. pneumoniae   and   S. aureus   and a few Gram-
negative bacteria. It remains unknown whether invasive bac-
terial disease in patients with IRAK-4 defi  ciency results from 
an upstream impairment of IL-1R and TLR signaling or a 
combination of both pathways, from the defective induction 
of one or a combination of specifi  c target genes downstream, 
or a combination of upstream and downstream defects. 
Impaired IL-1R and TLR2 signaling may play a role in the 
observed infections. Indeed, studies of experimental infection 
models in knockout mice have indicated that defense against 
  S. pneumoniae   and   S. aureus   may depend on IL-1R (  64, 65  ), 
TLR2 (  43, 66  ), and, for   S. pneumoniae  , perhaps also TLR4 
(  67, 68  ). Interestingly, the role of TLR2 in mouse defense 
against   S. pneumoniae   has been called into question in some 
experimental conditions (  69, 70  ). Impaired stimulation of 
TLR7, 8, and 9 is probably not involved in predisposition to 
pneumococcal disease, as UNC-93B  –  defi  cient patients with 
impaired TLR3, 7, 8, and 9 signaling do not suff  er from in-
vasive pneumococcal disease (  63  ). The impaired production 
of IL-6  –  inducible molecules, such as C-reactive protein 
(CrP), may also be involved. IRAK-4  –  defi  cient cells pro  duce 
small amounts of IL-6 in vitro upon activation with IL-1     
and TLR agonists. Moreover, most patients have weak or JEM VOL. 204, October 1, 2007 
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  Analysis of selectin (CD62L) shedding on granulocytes.     Granulocytes 
were isolated as described in the previous section, activated with TLR ago-
nists, stained with anti-CD62L  –  FITC (BD Biosciences) antibody, and ana-
lyzed by fl  ow cytometry, as previously described (  10  ). 
  Ex vivo analysis of PDCs and MDCs.     PBMCs were suspended at a fi  nal 
density of 2   
   10  6   cells/ml in RPMI supplemented with 10% FCS. They were 
incubated at 37  °  C, under an atmosphere containing 5% CO  2  , and stimulated 
with TLR agonists. 10     g/ml brefeldin A was added after 1 h of activation. 
After 3.5 h of activation, cells were washed and stained with anti-Lin1  –  FITC 
(BD Biosciences), anti-HLADR  –  PerCP (BD Biosciences), and anti-CD123  –
  PE-Cy7 (e-Bioscience) antibodies. For intracellular staining, PBMCs were 
permeabilized with the Cytofi  x/Cytoperm kit (BD Biosciences), according 
to the manufacturer  ’ s instructions. Anti  –  TNF-      –  allophycocyanin (BD Bio-
sciences) and anti  –  MIP-1      –  PE (BD Biosciences) antibodies were used to 
assess the response of MDCs and PDCs to TLR agonists. PBMCs were also 
incubated with the respective isotype controls, and cells were acquired on a 
three-laser fl  ow cytometer (LSR system; BD Biosciences). MDCs were 
defi  ned as Lin-1       , HLA-DR    , and CD123  low  , and PDCs were defi  ned as 
Lin-1       , HLA-DR    , and CD123  high  . For analysis, the quadrant for each individ-
ual tested was set such that 98% of PBMCs incubated with the respective 
isotype controls were negative for nonspecifi  c staining. 
  MDDCs.     MDDCs were prepared as previously described (  80  ). In brief, 
PBMCs were suspended in RPMI 1640 supplemented with 10% FCS, 
plated in cell culture fl  asks, and incubated for 1 h. Monocytes attached to 
the bottom of the culture fl  ask and nonadherent cells were removed with 
medium. Monocytes were then cultured in RPMI 1640 supplemented with 
10% FCS, 25 ng/ml GM-CSF, and 100 U/ml IL-4. GM-CSF and IL-4 were 
added to the medium every other day to maintain their initial concentrations. 
On day 7 or 8, some of the MDDCs were stained for CD1a and CD14. 
Living cells and cell debris were distinguished by forward/side scatter. 
More than 95% of living cells were CD1a    , and no CD14     cells were 
detected. On day 7 or 8, MDDCs were suspended in RPMI 1640 supple-
mented with 10% FCS at a density of 2   
   10  5  cells/ml, and supernatants were 
collected after 24 h of activation. The up-regulation of surface markers was 
assessed by collecting MDDCs and staining them with anti-CD1a  –  PE (BD 
Biosciences), anti-CD40  –  FITC (BD Biosciences), anti-CD80  –  FITC (BD 
Biosciences), and anti-CD86  –  FITC (BD Biosciences) antibodies. 
  Vaccination schedules of patients.     Patients were immunized against 
diphtheria and tetanus in accordance with international recommendations. 
Nine patients received multiple injections of glycan antigens (nonconjugated 
[  “  Pneumo23  ”  ] and conjugated [  “  Prevenar  ”  ] antipneumococcal vaccine), 
and their specifi  c antibody titers were subsequently monitored in detail. 
  Online supplemental material.     Fig. S1 demonstrates a deletion of the 
  IRAK4   locus on one allele in P2 and the presence of both   IRAK4   loci in P7. 
Fig. S2 shows the detailed results for each of the 11 cytokines for which a 
response to TLR agonists in healthy controls could be detected by multiplex 
assay. Table S1 shows blood leukocyte subsets in IRAK-4  –  defi  cient patients. 
Table S2 highlights T cell proliferation, Ig levels, and humoral responses to 
recall antigens and to glycans in IRAK-4  –  defi  cient patients. Table S3 off  ers 
the serology of patients to common viruses. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20070628/DC1. 
  We thank all members of the laboratory for helpful discussions, and Catherine 
Bidalled, Martine Courat, and Tony Leclerc for secretarial and technical assistance. 
We would particularly like to thank the patients and their families, whose trust, 
support, and cooperation were essential for collection of the data used in this study. 
  H. von Bernuth was supported by grants from the Deutsche 
Forschungsgemeinschaft (VO 995/1-1 and VO 995/1-2), from the European Ph.D. 
program of the San Raffaele Institute, and from the program   “  Legs Poix  ”   of the 
Parisian Universities. L. Mar  ó  di was supported by a grant from the Hungarian 
Research Fund (OTKA 49017), and A. Puel was supported by a grant from the 
European Union (QLK2-CT-2002-00846). The Laboratory of Human Genetics of 
  RNA and protein levels.     RNA was extracted from B-EBV and SV40-
fi  broblasts in TRI  zol   (Invitrogen), and cDNA was prepared using reverse 
transcriptase (SuperScript II; Invitrogen) for RT-PCR, according to the 
manufacturer  ’  s instructions. Proteins for Western blotting were extracted 
from B-EBV and SV40-fi  broblasts, and Western blots were probed with 
rabbit antibodies against IRAK  −  4 (Tularik) and GAPDH (Santa Cruz Bio-
technology, Inc.). 
  TLR agonists.     TLR agonists and cytokines were used at the following fi  nal 
concentrations, unless otherwise indicated: synthetic triacylated lipopeptide 
(PAM  3  CSK  4  , agonist of TLR1/2; Invivogen), 100 ng/ml; synthetic diacyl-
ated lipopeptide (PAM  2  CSK  4  , agonist of TLR2/6; Invivogen), 100 ng/ml; 
poly(I:C) (a synthetic analogue of dsRNA, polyinosine-polycytidylic acid, 
and nonspecifi  c TLR3 agonist; Invivogen), 25     g/ml; LPS (Re 595 from 
  Salmonella minnesota  , agonist of TLR-4; Sigma-Aldrich), 100 ng/ml; fl  agellin 
(TLR5 agonist; Invivogen), 1     g/ml; 3M-13 (TLR7 agonist) and 3M-2 
(TLR8 agonist; both provided by 3M Pharmaceuticals), 3     g/ml each; 
R-848, resiquimod hydrochloride (TLR7 and TLR8 agonist; provided 
by PharmaTech), 3     g/ml; and unmethylated CpG DNA CpG-C (C274; 
5    -TCGTCGAACGTTCGAGATGAT-3    ; TLR9 agonist; provided by 
R. Coff  man and F. Barrat, Dynavax Technologies, Berkeley, CA), 3     g/ml. 
Polymyxin B was used at 10     g/ml (Sigma-Aldrich). 
  B-EBV and SV40-fi  broblast activation.     We suspended 10  6   B-EBV cells 
per well in RPMI 1640 (Invitrogen) supplemented with 10% FCS (Invitro-
gen) and activated them by incubation with 3M-13, 3M-2, R-848, and 10      7   
M PMA plus 10      5   M ionomycin (Sigma-Aldrich) for 24 h. 10  5   SV40-fi  bro-
blast cells per well were seeded in DMEM (Invitrogen) supplemented with 
10% FCS in 24-well plates. Cells were activated with 20 ng/ml TNF-     
(R  &  D Systems), 10 ng/ml IL-1     (R  &  D Systems) and 10    −  7   M PMA plus 
10      5   M ionomycin the next day. The supernatants were harvested after 24 h 
of activation. 
  Cytokine measurement.     ELISA determinations of TNF-    , IL-6, and IL-10 
in cell culture supernatants were performed with a kit (PeliPair reagent set; 
Sanquin), according to the manufacturer  ’  s instructions. Optical density was 
determined by an automated ELISA reader (MR5000; Thermolab Systems). 
We used a fl  uorescence-based assay (a human cytokine 25-plex antibody bead 
kit) that can detect 25 cytokines (LHC0009; Biosource International) for 
the simultaneous determination of multiple cytokines. Fluorescence was mea-
sured with a 100 IS system (Luminex Corporation). The assay and analysis 
were performed according to the manufacturer  ’  s instructions. 
  Cell purifi  cation and activation.     Blood samples from healthy controls 
or patients were collected into heparin-containing tubes, and PBMCs and 
granulocytes were separated by Ficoll-gradient centrifugation. The patients 
were of diff  erent ages when the experiments were performed, ranging 
from 7 to 32 yr old. For granulocyte isolation, erythrocytes were lysed and 
washed twice in PBS. More than 95% of the granulocytes purifi  ed on 
Ficoll were CD15    . We did not purify granulocytes by fl  ow cytometry, as 
the surface expression and TLR-induced shedding of L-selectin (CD62L) 
were not better detected (unpublished data).The PBMC preparation was 
enriched in T cells, B cells, monocytes, and NK cells by magnetic bead 
isolation using anti-CD3, -CD19, -CD14, and -CD56 microbeads (Miltenyi 
Biotec), according to the manufacturer  ’  s instructions. Purifi  ed T cells were 
labeled with anti-CD3  –  FITC (BD Biosciences), B cells with anti-CD19  –  PE 
(BD Biosciences), monocytes with anti-CD14  –  FITC (BD Biosciences), and 
NK cells with anti-CD3  –  FITC/anti-CD56  –  PE (BD Biosciences) anti-
bodies, and sorting was performed on a fl  ow cytometer (FACSVantage; 
BD Biosciences). The isolated cells were cultured in RPMI 1640 supple-
mented with 10% FCS, with immediate TLR agonist stimulation. We added 
100 U/ml IL-2 to cultures of purifi  ed T cells. Purifi  ed B cells were sus-
pended in RPMI 1640 supplemented with 10% FCS at a density of 
10  6   cells/ml. Cells were stimulated with TLR agonists together with 100 U/ml 
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